8 results on '"Schouten, Harry C."'
Search Results
2. Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission.
- Author
-
Versluis, Jurjen, Kalin, Burak, Zeijlemaker, Wendelien, Passweg, Jakob, Graux, Carlos, Manz, Markus G., Vekemans, Marie-Christiane, Biemond, Bart J., Legdeur, Marie-Cecile J.C., Kooy, Marinus van Marwijk, de Weerdt, Okke, Wijermans, Pierre W., Hoogendoorn, Mels, Bargetzi, Mario J., Kuball, Juergen, Schouten, Harry C., van der Velden, Vincent H.J., Janssen, Jeroen J.W.M., Pabst, Thomas, and Lowenberg, Bob
- Subjects
ACUTE myeloid leukemia ,HEMATOPOIETIC stem cell transplantation ,CANCER remission ,TRANSPLANTATION of organs, tissues, etc. - Abstract
Purpose: The detection of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) may improve future risk-adapted treatment strategies. We assessed whether MRD-positive and MRD-negative patients with AML benefit differently from the graft-versus-leukemia effect of allogeneic hematopoietic stem-cell transplantation (alloHSCT). Methods: A total of 1,511 patients were treated in subsequent Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research AML trials, of whom 547 obtained a first complete remission, received postremission treatment (PRT), and had available flow cytometric MRD before PRT. MRD positivity was defined as more than 0.1% cells with a leukemia-associated immunophenotype within the WBC compartment. PRT consisted of alloHSCT (n = 282), conventional PRT by a third cycle of chemotherapy (n = 160), or autologous hematopoietic stem-cell transplantation (n = 105). Results: MRD was positive in 129 patients (24%) after induction chemotherapy before proceeding to PRT. Overall survival and relapse-free survival were significantly better in patients without MRD before PRT compared with MRD-positive patients (65% ± 2% v 50% ± 5% at 4 years; P =.002; and 58% ± 3% v 38% ± 4%; P <.001, respectively), which was mainly because of a lower cumulative incidence of relapse (32% ± 2% compared with 54% ± 4%; P <.001, respectively). Multivariable analysis with adjustment for covariables showed that the incidence of relapse was significantly reduced after alloHSCT compared with chemotherapy or autologous hematopoietic stem cell transplantation (hazard ratio [HR], 0.36; P <.001), which was similarly exerted in both MRD-negative and MRD-positive patients (HR, 0.38; P <.001; and HR, 0.35; P <.001, respectively). Conclusion: The graft-versus-leukemia effect of alloHSCT is equally present in MRD-positive and MRD-negative patients, which advocates a personalized application of alloHSCT, taking into account the risk of relapse determined by AML risk group and MRD status, as well as the counterbalancing risk of nonrelapse mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- Author
-
Yeshurun, Moshe, Labopin, Myriam, Blaise, Didier, Cornelissen, Jan J., Sengeloev, Henrik, Vindelov, Lars, Kuball, Juergen, Chevallier, Patrice, Craddock, Charles, Socie, Gerard, Bilger, Karin, Schouten, Harry C., Fegueux, Nathalie, Goker, Hakan, Maertens, Johan, Bunjes, Donald, Arnold, Renate, Nagler, Arnon, and Mohty, Mohamad
- Subjects
DRUG therapy ,STEM cell transplantation ,ACUTE myeloid leukemia treatment ,STEM cell treatment ,TRANSPLANTATION of organs, tissues, etc. - Abstract
BACKGROUND The objective of the current study was to investigate the role of postremission consolidation chemotherapy before reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) for patients with acute myeloid leukemia (AML) in first complete remission (CR1). METHODS Of the 789 consecutive patients with AML in CR1 who underwent RIC alloSCT from a human leukocyte antigen-matched sibling or matched unrelated donor peripheral stem cell grafts between 2001 and 2010, 591 patients received at least 1 cycle of consolidation chemotherapy and 198 patients did not receive any consolidation chemotherapy before alloSCT. To minimize inherent survival bias in favor of patients who underwent transplant long after achieving CR1, the study focused on 373 patients who underwent transplant within the median time frame between achievement of CR1 and alloSCT (3 months for patients who underwent alloSCT from matched siblings and 4 months for patients who underwent alloSCT from matched unrelated donors). In this subgroup, 151 patients did not receive any consolidation chemotherapy and 222 patients received ≥ 1 consolidation chemotherapy cycle. RESULTS With a median follow-up of 36 months (range, 2 months-135 months), the 3-year cumulative recurrence incidence (RI) was not significantly different between the groups (36% ± 4% for the group treated without consolidation chemotherapy vs 38% ± 3% for patients who received consolidation chemotherapy; P = .89). In addition, leukemia-free survival was similar between the groups (45% ± 4% and 47% ± 3%, respectively; P = .41). Dose intensity of cytarabine given during consolidation chemotherapy appeared to have no influence on RI. On multivariate analysis, pretransplant consolidation (≥ 1 cycle vs 0 cycles) was found to have no significant impact on RI (hazards ratio, 1.29; 95% confidence interval, 0.84-1.97 [ P = .24]) or leukemia-free survival (hazards ratio, 1.00; 95% confidence interval, 0.71-1.42 [ P = .99]). CONCLUSIONS The data from the current study suggest no apparent advantage for postremission consolidation chemotherapy before RIC alloSCT, provided a donor is readily available. Cancer 2014;120:855-863. © 2013 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).
- Author
-
Ossenkoppele, Gert J., Stussi, Georg, Maertens, Johan, Montfort, Kees van, Biemond, Bart J., Breems, Dimitri, Ferrant, August, Graux, Carlos, de Greet, Georgine E., Halkes, C. J. M., Hoogendoorn, Mels, Hollestein, Rene M., Jongen-Lavrencic, Mojca, Levin, Mark D., van de Loosdrecht, Arjan A., Marwijk Kooij, Marinus van, Norden, Yvette van, Pabst, Thomas, Schouten, Harry C., and Vellenga, Edo
- Subjects
- *
BEVACIZUMAB , *ACUTE myeloid leukemia , *CYTARABINE , *CLINICAL trials , *DRUG therapy , *CANCER research - Abstract
An urgent need for new treatment modalities is emerging in elderly patients with acute myeloid leukemia (AML). We hypothesized that targeting VEGF might furnish an effective treatment modality in this population. Elderly patients with AML were randomly assigned in this phase 2 study (n = 171) to receive standard chemotherapy (3 + 7) with or without bevacizumab at a dose of 10 mg/kg intravenously at days 1 and 15. In the second cycle, patients received cytarabine 1000 mg/m2 twice daily on days 1-6 with or without bevacizumab. The complete remission rates in the 2 arms were not different (65%). Event-free survival at 12 months was 33% for the standard arm versus 30% for the bevacizumab arm; at 24 months, it was 22% and 16%, respectively (P = .42). The frequencies of severe adverse events (SAEs) were higher in the bevacizumab arm.(n = 63) compared with the control arm (n = 28; P = .043), but the percentages of death or life-threatening SAEs were lower in the bevacizumab arm (60% vs 75% of SAEs). The results of the present study show that the addition of bevacizumab to standard chemotherapy does not improve the therapeutic out-come of older AML patients. This trial is registered as number NTR904 in The Netherlands Trial Register (www.trialregister.nI). [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.
- Author
-
Pabst, Thomas, Vellenga, Edo, van Putten, Wim, Schouten, Harry C., Graux, Carlos, Vekemans, Marie-Christiane, Biemond, Bart, Sonneveld, Peter, Passweg, Jakob, Verdonck, Leo, Legdeur, Marie-Cecile, Theobald, Matthias, Jacky, Emanuel, Bargetzi, Mario, Maertens, Johan, Ossenkoppele, Gert Jan, and Löwenberg, Bob
- Subjects
- *
GRANULOCYTE-colony stimulating factor , *ACUTE myeloid leukemia , *CYTARABINE , *DRUG therapy , *PHARMACEUTICAL arithmetic , *MEDICAL statistics - Abstract
The clinical value of chemotherapy sensitization of acute myeloid leukemia (AML) with G-CSF priming has remained controversial. Cytarabine is a key constituent of remission induction chemotherapy. The effect of G-CSF priming has not been investigated in relationship with variable dose levels of cytarabine. We randomized 917 AML patients to receive G-CSF (456 patients) or no G-CSF (461 patients) at the days of chemotherapy. In the initial part of the study, 406 patients were also randomized between 2 cytarabine regimens comparing conventional-dose (199 patients) versus escalated-dose (207 patients) cytarabine in cycles 1 and 2. We found that patients after induction chemotherapy plus G-CSF had similar overall survival (43% vs 40%, P = .88), event-free survival (37% vs 31%, P = .29), and relapse rates (34% vs 36%, P = .77) at 5 years as those not receiving G-CSF. However, patients treated with the escalated-dose cytarabine regimen benefited from G-CSF priming, with improved event-free survival (P = .01) and overall survival (P = .003), compared with patients without G-CSF undergoing escalated-dose cytarabine treatment. A significant survival advantage of sensitizing AML for chemotherapy with G-CSF was not apparent in the entire study group, but it was seen in patients treated with escalated-dose cytarabine during remission induction. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study
- Author
-
Armand, Philippe, Kim, Haesook T., Zhang, Mei-Jie, Perez, Waleska S., Dal Cin, Paola S., Klumpp, Thomas R., Waller, Edmund K., Litzow, Mark R., Liesveld, Jane L., Lazarus, Hillard M., Artz, Andrew S., Gupta, Vikas, Savani, Bipin N., McCarthy, Philip L., Cahn, Jean-Yves, Schouten, Harry C., Finke, Jürgen, Ball, Edward D., Aljurf, Mahmoud D., and Cutler, Corey S.
- Subjects
- *
CYTOGENETICS , *MYELOID leukemia , *CANCER patients , *HOMOGRAFTS , *STEM cell transplantation , *KARYOTYPES , *ACUTE myeloid leukemia - Abstract
Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia.
- Author
-
Löwenberg, Bob, Ossenkoppele, Gert J., van Putten, Wim, Schouten, Harry C., Graux, Carlos, Ferrant, Augustin, Sonneveld, Pieter, Maertens, Johan, Jongen-Lavrencic, Mojca, von Lilienfeld-Toal, Marie, Biemond, Bart J., Vellenga, Edo, van Marwijk Kooy, Marinus, Verdonck, Leo F., Beck, Joachim, Döhner, Hartmut, Gratwohl, Alois, Pabst, Thomas, and Verhoef, Gregor
- Subjects
- *
ACUTE myeloid leukemia , *DISEASES in older people , *CYTARABINE , *HEMATOLOGY , *CANCER patients , *LEUCOCYTOSIS - Abstract
Background: A complete remission is essential for prolonging survival in patients with acute myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the optimal dose is unknown. In older patients, it is usual to give daunorubicin at a dose of 45 to 50 mg per square meter of body-surface area. Methods: Patients in whom AML or high-risk refractory anemia had been newly diagnosed and who were 60 to 83 years of age (median, 67) were randomly assigned to receive cytarabine, at a dose of 200 mg per square meter by continuous infusion for 7 days, plus daunorubicin for 3 days, either at the conventional dose of 45 mg per square meter (411 patients) or at an escalated dose of 90 mg per square meter (402 patients); this treatment was followed by a second cycle of cytarabine at a dose of 1000 mg per square meter for 6 days. The primary end point was event-free survival. Results: The complete remission rates were 64% in the group that received the escalated dose of daunorubicin and 54% in the group that received the conventional dose (P=0.002); the rates of remission after the first cycle of induction treatment were 52% and 35%, respectively (P<0.001). There was no significant difference between the two groups in the incidence of hematologic toxic effects, 30-day mortality (11% and 12% in the two groups, respectively), or the incidence of moderate, severe, or life-threatening adverse events (P=0.08). Survival end points in the two groups did not differ significantly overall, but patients in the escalated-treatment group who were 60 to 65 years of age, as compared with the patients in the same age group who received the conventional dose, had higher rates of complete remission (73% vs. 51%), event-free survival (29% vs. 14%), and overall survival (38% vs. 23%). Conclusions: In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional dose, without additional toxic effects. (Current Controlled Trials number, ISRCTN77039377; and Netherlands National Trial Register number, NTR212.) N Engl J Med 2009;361:1235-48. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
8. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia:: A randomised phase II trial from HOVON, the Dutch–Belgian Haemato-Oncology Working Group for adults
- Author
-
Daenen, Simon, van der Holt, Bronno, Verhoef, Gregor E.G., Löwenberg, Bob, Wijermans, Pierre W., Huijgens, Peter C., van Marwijk Kooy, Rien, Schouten, Harry C., Kramer, Mark H.H., Ferrant, Augustin, van den Berg, Eva, Steijaert, Monique M.C., Verdonck, Leo F., and Sonneveld, Pieter
- Subjects
- *
CYCLOSPORINE , *ACUTE myeloid leukemia , *IMMUNOSUPPRESSIVE agents , *MYELOID leukemia - Abstract
Cyclosporin A (CsA) inhibits the P-gp pump that can be responsible for failure of cytostatic treatment in acute myeloid leukaemia (AML). Eighty patients with relapsing/refractory AML were randomly assigned to mitoxantrone (M) and etoposide (VP) (MVP) in unmitigated antileukaemic doses with or without CsA, to investigate if toxicity was manageable and if antileukaemic therapy could be improved. CsA did not delay haematological recovery, but fewer CsA patients received post-induction therapy because of haematological and non-haematological toxicity. CR rate was 43% for MVP and 53% for CsA; DFS was 9 and 8 months, and OS 8 and 9 months, respectively. Seventeen of 38 CR patients proceeded to stem cell transplantation (SCT). After a median follow-up of 66 months, six patients were still alive. Addition of CsA did not improve treatment outcome, possibly due to inadequate post-induction therapy as a result of increased toxicity. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.